Earlier this year a megamerger between Quintiles, the world’s largest CRO, and healthcare data and consultancy firm IMS was announced, with the combined company branded as Quintiles IMS. With a
![Danaher Corporation Strengthens Diagnostics Offerings with $4B Acquisition of Cepheid](https://evolution-bio.com/wp-content/uploads/2016/09/160907-danaher-cepheid-bio.jpg)
Danaher Corporation has announced the acquisition of medical diagnostics company Cepheid, strengthening their presence in the Molecular Diagnostics market. Danaher will pay $53 per share in cash, a premium of
![Pfizer to Buy Medivation for $14 Billion, But Who Are the Real Winners?](https://evolution-bio.com/wp-content/uploads/2016/08/160822-pfizer-medivation-bio.jpg)
Pharmaceutical giants Pfizer are expanding their cancer portfolio through the $14B acquisition of California-based biopharmaceutical company Medivation. The acquisition follows two recent unsuccessful bids for Medivation by Sanofi, as well
![2016 US Venture Capital Investment into Life Sciences Companies: An Analysis by Evolution Bioscience](https://evolution-bio.com/wp-content/uploads/2016/08/160802-vc-investment-evobio.jpg)
In order to elucidate the focus of Venture Capital funding in the Biotechnology sector this year, Evolution Analysts have assessed the deals carried out by the Top 25 US Venture
![M&A Analysis: Bio-Techne enters Genomics market with $250M acquisition of Advanced Cell Diagnostics](https://evolution-bio.com/wp-content/uploads/2016/07/160711-biotechne-acd-biosci.jpg)
Bio-Techne Corporation have agreed to acquire California-based molecular pathology company Advanced Cell Diagnostics for $250 million in cash plus additional potential milestone payments of up to $75M. The acquisition marks
![Will Mesoblast recover from Teva & Celgene setbacks?](https://evolution-bio.com/wp-content/uploads/2016/06/160628-mesoblast-biosci.jpg)
Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, with their key US
![Texcell acquisition of Vivo Science underscores the shifting Biopharma Contract Services landscape](https://evolution-bio.com/wp-content/uploads/2016/06/160620-texcell-vivo-biosci.jpg)
Texcell, a French provider of biosafety contract services, recently acquired German company Vivo Science GmbH, a GLP/GMP compliant contract research test facility specialising in toxicology, immunology & virology in vivo
![Thermo Fisher to Acquire FEI Company for $4.2B](https://evolution-bio.com/wp-content/uploads/2016/05/160531-thermo-FEI-biosci.jpg)
Thermo Fisher Scientific have further cemented their reputation as a serial acquirer with the purchase of FEI Company for approximately $4.2B in cash. Oregon-based FEI Company are world leaders in
![Further AgriBusiness Consolidation as Bayer Makes a $62B Bid for Monsanto](https://evolution-bio.com/wp-content/uploads/2016/05/160524-bayer-monsanto-evobio.jpg)
Last week German multinational Bayer put forward an all-cash $62B bid for American AgTech giant Monsanto, further emphasizing the unprecedented period of consolidation that the global AgriBusiness market is currently
![Cell Therapy Ltd grants Japanese Licence for its Heart Regeneration Medicine to Daiichi Sankyo](https://evolution-bio.com/wp-content/uploads/2016/05/160518-evobio-celltherapy-daiichisankyo.jpg)
Welsh stem cell company Cell Therapy Ltd. has granted Japanese drugmaker Daiichi Sankyo a license for Heartcelâ„¢, its promising cardiac regeneration medicine. Under the conditions of the deal, Daiichi Sankyo